Results 41 to 50 of about 14,250,657 (303)

Differential drug resistance acquisition in HIV-1 of subtypes B and C. [PDF]

open access: yesPLoS ONE, 2007
BACKGROUND: Subtype C is the most prevalent HIV-1 subtype in the world, mainly in countries with the highest HIV prevalence. However, few studies have evaluated the impact of antiretroviral therapy on this subtype.
Esmeralda A J M Soares   +7 more
doaj   +1 more source

Neisseria meningitidis Subtype Nomenclature

open access: yesClinical Diagnostic Laboratory Immunology, 1999
We believe the novel subtyping nomenclature proposed for Neisseria meningitidis ([7][1]) is flawed and, if adopted, will create chaos for meningococcal epidemiology with serious implications for public health monitoring and vaccine development.
M C, Maiden   +3 more
openaire   +2 more sources

Neutralization Susceptibility of B Subtype Variant B′′ Primary HIV‐1 Isolates

open access: yes, 1998
The HEC/FIOCRUZ Aids Clinical Research Groupp: V. G. V. SANTOS, V. C. Rolla, S. Cavalcante, M. C. G. Galhardo and M. R. C. Guimarães.Susceptibility to autologous and heterologous neutralization of primary human immunodeficiency virus (HIV)-1 isolates ...
Bongertz, Vera   +14 more
core   +1 more source

Phylodynamic profile of HIV-1 subtype B, CRF01_AE and the recently emerging CRF51_01B among men who have sex with men (MSM) in Singapore. [PDF]

open access: yesPLoS ONE, 2013
HIV-1 subtype B and CRF01_AE are the predominant infecting subtypes among men who have sex with men (MSM) in Singapore. The genetic history, population dynamics and pattern of transmission networks of these genotypes remain largely unknown. We delineated
Kim Tien Ng   +12 more
doaj   +1 more source

Pediatric Idiopathic Multicentric Castleman Disease Is Often Severe But Responsive to Siltuximab

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background Idiopathic multicentric Castleman disease (iMCD) is a potentially fatal immunologic disorder marked by widespread lymphadenopathy and inflammation. Siltuximab, an interleukin‐6 (IL‐6) inhibitor, is the only FDA‐approved treatment for adult patients with iMCD.
Bridget Austin   +17 more
wiley   +1 more source

Scatter plots of FC of subtype C amplicons recombined in subtype B and subtype C backbones.

open access: yes, 2013
(A–D) X-axis: Subtype B and Y-axis: subtype C for 1346 pairs; Black line x = y; (A) all drug classes (R2 = 0.88); (B) NRTIs (R2 = 0.88); (C) NNRTIs (R2 = 0.90); (D) PIs (R2 = 0.87); (E) Analysis of the pair-wise comparison of differences in FCs per clone
David Nauwelaers (350953)   +10 more
core   +1 more source

HIV-1 subtype B: Traces of a pandemic

open access: yesVirology, 2016
Human migration is a major process that shaped the origin and dissemination of HIV. Within HIV-1, subtype B (HIV-1B) is the most disseminated variant and it is assumed to be the causative agent in approximately 11% of all cases of HIV worldwide. Phylogenetic studies have revealed that HIV-1B emerged in Kinshasa (Africa) and was introduced into the ...
Dennis Maletich, Junqueira   +1 more
openaire   +2 more sources

Venetoclax‐Based Therapy as a Bridge to Hematopoietic Stem Cell Transplantation in Relapsed or Refractory Pediatric Acute Leukemia

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Relapsed and/or refractory (R/R) pediatric acute leukemia carries a dismal prognosis, largely driven by chemoresistance to conventional salvage therapy. The BH3‐mimetic venetoclax, combined with chemotherapy or hypomethylating agents, has demonstrated efficacy in small clinical trials.
Katherine S. Colman   +9 more
wiley   +1 more source

HIV-1 subtype B sequences.

open access: yes, 2014
HIV-1 subtype B sequences.
Yaxelis Mendoza (508647)   +9 more
core   +1 more source

Genetic and immunological characterization of new subtype G envelope expressing HIV-1 pseudoviruses [PDF]

open access: yes, 2014
Includes bibliographical references.One of the greatest challenges for the development of an effective HIV-1 vaccine is the high genetic diversity of this pathogen and the complex escape mechanisms employed by the envelope gp120 and gp41 glycoprotein ...
Essomba, Rene Ghislain
core   +1 more source

Home - About - Disclaimer - Privacy